🚀 VC round data is live in beta, check it out!
Divi's Laboratories Valuation Multiples
Discover revenue and EBITDA valuation multiples for Divi's Laboratories and similar public comparables like Zhejiang NHU, Wuxi Biologics, Sartorius, Medpace and more.
Divi's Laboratories Overview
About Divi's Laboratories
Divi's Laboratories Ltd is a specialty and generic drug manufacturing company. It is engaged in the manufacture of Active Pharmaceutical ingredients (API), Intermediates, and Nutraceutical ingredients, with a predominance in exports. It also, through its custom synthesis, supports pharma companies for their patented products business from gram-scale requirements for clinical trials to launch, as well as late-life cycle management. Geographically, the company derives maximum revenue from Europe, and the rest from America, India, Asia (excluding India), and the Rest of the world.
Founded
1990
HQ
Employees
9.1K
Website
Financials (LTM)
EV
$17B
Divi's Laboratories Financials
Divi's Laboratories reported last 12-month revenue of $1B and EBITDA of $377M.
In the same LTM period, Divi's Laboratories generated $702M in gross profit, $377M in EBITDA, and $277M in net income.
Revenue (LTM)
Divi's Laboratories P&L
In the most recent fiscal year, Divi's Laboratories reported revenue of $1B and EBITDA of $351M.
Divi's Laboratories expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $1B | XXX | $1B | XXX | XXX | XXX |
| Gross Profit | $702M | XXX | $577M | XXX | XXX | XXX |
| Gross Margin | 61% | XXX | 53% | XXX | XXX | XXX |
| EBITDA | $377M | XXX | $351M | XXX | XXX | XXX |
| EBITDA Margin | 33% | XXX | 32% | XXX | XXX | XXX |
| EBIT Margin | 29% | XXX | 28% | XXX | XXX | XXX |
| Net Profit | $277M | XXX | $257M | XXX | XXX | XXX |
| Net Margin | 24% | XXX | 24% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Divi's Laboratories Stock Performance
Divi's Laboratories has current market cap of $17B, and enterprise value of $17B.
Market Cap Evolution
Divi's Laboratories' stock price is $64.23.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $17B | $17B | -2.3% | XXX | XXX | XXX | $0.97 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialDivi's Laboratories Valuation Multiples
Divi's Laboratories trades at 14.6x EV/Revenue multiple, and 44.4x EV/EBITDA.
EV / Revenue (LTM)
Divi's Laboratories Financial Valuation Multiples
As of April 14, 2026, Divi's Laboratories has market cap of $17B and EV of $17B.
Equity research analysts estimate Divi's Laboratories' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Divi's Laboratories has a P/E ratio of 61.5x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $17B | XXX | $17B | XXX | XXX | XXX |
| EV (current) | $17B | XXX | $17B | XXX | XXX | XXX |
| EV/Revenue | 14.6x | XXX | 15.3x | XXX | XXX | XXX |
| EV/EBITDA | 44.4x | XXX | 47.6x | XXX | XXX | XXX |
| EV/EBIT | 50.6x | XXX | 55.0x | XXX | XXX | XXX |
| EV/Gross Profit | 23.8x | XXX | 29.0x | XXX | XXX | XXX |
| P/E | 61.5x | XXX | 66.2x | XXX | XXX | XXX |
| EV/FCF | 191.3x | XXX | 423.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Divi's Laboratories Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Divi's Laboratories Margins & Growth Rates
Divi's Laboratories' revenue in the last 12 month grew by 16%.
Divi's Laboratories' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.
Divi's Laboratories' rule of 40 is 50% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Divi's Laboratories' rule of X is 74% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Divi's Laboratories Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 16% | XXX | 4% | XXX | XXX | XXX |
| EBITDA Margin | 33% | XXX | 32% | XXX | XXX | XXX |
| EBITDA Growth | 21% | XXX | 6% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 50% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 74% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 15% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 0% | XXX | 0% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 28% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Divi's Laboratories Public Comps
See public comps and valuation multiples for other Contract Research & Manufacturing and Nutraceuticals & Cosmeceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Divi's Laboratories | XXX | XXX | XXX | XXX | XXX | XXX |
| Zhejiang NHU | XXX | XXX | XXX | XXX | XXX | XXX |
| Wuxi Biologics | XXX | XXX | XXX | XXX | XXX | XXX |
| Sartorius | XXX | XXX | XXX | XXX | XXX | XXX |
| Medpace | XXX | XXX | XXX | XXX | XXX | XXX |
| Yunnan Baiyao Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Divi's Laboratories M&A Activity
Divi's Laboratories acquired XXX companies to date.
Last acquisition by Divi's Laboratories was on XXXXXXXX, XXXXX. Divi's Laboratories acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Divi's Laboratories
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialDivi's Laboratories Investment Activity
Divi's Laboratories invested in XXX companies to date.
Divi's Laboratories made its latest investment on XXXXXXXX, XXXXX. Divi's Laboratories invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Divi's Laboratories
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Divi's Laboratories
| When was Divi's Laboratories founded? | Divi's Laboratories was founded in 1990. |
| Where is Divi's Laboratories headquartered? | Divi's Laboratories is headquartered in India. |
| How many employees does Divi's Laboratories have? | As of today, Divi's Laboratories has over 9K employees. |
| Who is the CEO of Divi's Laboratories? | Divi's Laboratories' CEO is Satchandra Kiran Divi. |
| Is Divi's Laboratories publicly listed? | Yes, Divi's Laboratories is a public company listed on National Stock Exchange of India. |
| What is the stock symbol of Divi's Laboratories? | Divi's Laboratories trades under DIVISLAB ticker. |
| When did Divi's Laboratories go public? | Divi's Laboratories went public in 2003. |
| Who are competitors of Divi's Laboratories? | Divi's Laboratories main competitors are Zhejiang NHU, Wuxi Biologics, Sartorius, Medpace. |
| What is the current market cap of Divi's Laboratories? | Divi's Laboratories' current market cap is $17B. |
| What is the current revenue of Divi's Laboratories? | Divi's Laboratories' last 12 months revenue is $1B. |
| What is the current revenue growth of Divi's Laboratories? | Divi's Laboratories revenue growth (NTM/LTM) is 16%. |
| What is the current EV/Revenue multiple of Divi's Laboratories? | Current revenue multiple of Divi's Laboratories is 14.6x. |
| Is Divi's Laboratories profitable? | Yes, Divi's Laboratories is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Divi's Laboratories? | Divi's Laboratories' last 12 months EBITDA is $377M. |
| What is Divi's Laboratories' EBITDA margin? | Divi's Laboratories' last 12 months EBITDA margin is 33%. |
| What is the current EV/EBITDA multiple of Divi's Laboratories? | Current EBITDA multiple of Divi's Laboratories is 44.4x. |
| What is the current FCF of Divi's Laboratories? | Divi's Laboratories' last 12 months FCF is $87M. |
| What is Divi's Laboratories' FCF margin? | Divi's Laboratories' last 12 months FCF margin is 8%. |
| What is the current EV/FCF multiple of Divi's Laboratories? | Current FCF multiple of Divi's Laboratories is 191.3x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.